Vetr Crowd Doesn't Like Outlook For Clovis Oncology

On Wednesday, the Vetr crowd downgraded their rating for Clovis Oncology Inc CLVS from 3 stars (Hold) to 2.5 stars (Sell). Sentiment of the stock among Vetr users is also down, with 85 percent of crowd ratings bearish.

Like most companies in the biotech sector, shares of the cancer treatment biopharmaceutical company saw a hefty 34 percent bump following the election, cresting at $36.70 last week. The stock traded recently at $36.12.

However, a reported Q3 loss of $1.70 per share as well as questions of efficacy and potential health risks surrounding the launch of rucaparib, Clovis Oncology's new ovarian cancer treatment medication, has created a some anxiety among investors.

See how crowdsourced ratings can help you time the market.

The Vetr Crowd’s average target price is down at $33.59, which is below the average analyst target price of $37.82. Less than 2 percent of Vetr users are holding CLVS in their watch lists.